Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuan Peng

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Journal of Pharmaceutical Policy and Practice|July 19, 2024
Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysisWei Kang, Kuan Peng, Vincent K C Yan, et al.
Eclinicalmedicine|August 28, 2023
Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort studyKuan Peng, Xue Li, Deliang Yang, et al.
Studies in Health Technology and Informatics|August 8, 2025
Predicting Infection Risk in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs: An Application of Machine LearningKuan Peng, Deliang Yang, Jiaqi Wang, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 23, 2023
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series AnalysisKuan Peng, Joseph E Blais, Nicole L Pratt, et al.
The Journal of Infection|December 20, 2022
Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)Xue Li, Kuan Peng, Franco W T Cheng, et al.
Vaccine|February 10, 2022
Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoringFrancisco Tsz Tsun Lai, Miriam Tim Yin Leung, Edward Wai Wa Chan, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Journal of Pharmaceutical Policy and Practice|July 19, 2024
Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysisWei Kang, Kuan Peng, Vincent K C Yan, et al.
Eclinicalmedicine|August 28, 2023
Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort studyKuan Peng, Xue Li, Deliang Yang, et al.
Studies in Health Technology and Informatics|August 8, 2025
Predicting Infection Risk in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs: An Application of Machine LearningKuan Peng, Deliang Yang, Jiaqi Wang, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 23, 2023
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series AnalysisKuan Peng, Joseph E Blais, Nicole L Pratt, et al.
The Journal of Infection|December 20, 2022
Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)Xue Li, Kuan Peng, Franco W T Cheng, et al.
Vaccine|February 10, 2022
Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoringFrancisco Tsz Tsun Lai, Miriam Tim Yin Leung, Edward Wai Wa Chan, et al.
Pageof 8